Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Bristol-Myers Squibb
M.D. Anderson Cancer Center
InSightec
University of Pittsburgh
ImmunityBio, Inc.
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
Bristol-Myers Squibb
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Boehringer Ingelheim
M.D. Anderson Cancer Center
Novartis
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Brown University
Aulos Bioscience, Inc.
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Dragonfly Therapeutics
Dragonfly Therapeutics
Gilead Sciences
Bristol-Myers Squibb
Fred Hutchinson Cancer Center
Exelixis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
VA Office of Research and Development
Thomas Jefferson University
Ankara Etlik City Hospital
Myeloid Therapeutics
Hackensack Meridian Health
Medical University of South Carolina
Replimune, Inc.
Emory University
Fondazione Ricerca Traslazionale
Ohio State University Comprehensive Cancer Center
Gazi University
Genentech, Inc.
Hefei TG ImmunoPharma Co., Ltd.
Bristol-Myers Squibb
Washington University School of Medicine
Big Ten Cancer Research Consortium